{"preliminary_commentary":{"by_channel":{"x_thread":2,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05652686","nct_id":"NCT05652686","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05652686. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"A standard 3+3 dose escalation design will be employed.","label":"Part A: Dose Escalation","type":"EXPERIMENTAL"},{"description":"Part B cohorts will open after the dose level considered for RDE has been cleared in Parts A, C and D.","label":"Part B: Dose Expansion","type":"EXPERIMENTAL"},{"description":"Part C of the study will include substudies C1 to C5, combining Peluntamig (PT217) with chemotherapy.","label":"Part C: Chemotherapy Combination Therapy","type":"EXPERIMENTAL"},{"description":"In part D, Peluntamig (PT217) will be given in combination with atezolizumab, either alone or in combination with chemotherapy.","label":"Part D: ICI Combination Therapy","type":"EXPERIMENTAL"}],"collaborators":["Hoffmann-La Roche"],"completion_date":{"date":"2028-08","type":"ESTIMATED"},"conditions":["Small Cell Lung Cancer (SCLC)","Large Cell Neuroendocrine Cancer (LCNEC)","Neuroendocrine Prostate Cancer (NEPC)","Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)","Neuroendocrine Carcinomas (NEC)","Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)"],"enrollment":{"count":203,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Peluntamig (PT217)","otherNames":[],"type":"DRUG"},{"name":"Carboplatin + Etoposide","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel.","otherNames":[],"type":"DRUG"},{"name":"Atezolizumab","otherNames":[],"type":"DRUG"},{"name":"Lurbinectedin","otherNames":[],"type":"DRUG"},{"name":"Irinotecan (drug)","otherNames":[],"type":"DRUG"},{"name":"Topotecan","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-15","lead_sponsor":"Phanes Therapeutics","official_title":"An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"To determine recommended dose for expansion (RDE) of Peluntamig (PT217).","timeFrame":"Through study completion, up to approximately 3 years."},{"measure":"To evaluate the safety and tolerability of Peluntamig (PT217).","timeFrame":"Through study completion, up to approximately 3 years."},{"measure":"To evaluate the efficacy of Peluntamig (PT217) monotherapy or in combination treatments as assessed by ORR.","timeFrame":"Through study completion, up to approximately 3 years."}],"references":[],"start_date":{"date":"2023-09-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)","url":"https://clinicaltrials.gov/study/NCT05652686"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05652686"}